FDA stamps fast OK on Astellas' pioneering FLT3 AML drug gilteritinib, expanding on a record year for new approvals

Astellas has picked up boasting rights to gaining the first FDA approval of a FLT3 inhibitor for a specific group of FLT3 positive acute myeloid leukemia patients — which accounts for close to a third of the population.